Video Experimental Relacionado
Updated: Sep 8, 2025
13:18
Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
1.3K
Orientación hacia el eje Keap1/Nrf2 en el cáncer: mecanismos moleculares e intervenciones farmacológicas
Yangchen Xia1, Ziyang Xu1, Xun Yuan2
1Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Investigational new drugs
|September 5, 2025
Resumen
El factor 2 relacionado con el factor eritreo 2 (Nrf2) regula las vías protectoras, pero también promueve el cáncer. La inhibición de Nrf2 ofrece una estrategia potencial de tratamiento del cáncer, especialmente para los cánceres relacionados con la inflamación.
Área de la Ciencia:
- Biología molecular
- Investigación del cáncer
- Farmacología
Sus antecedentes:
- El factor nuclear eritroide 2 (Nrf2) es un regulador clave de los mecanismos citoprotectores, incluida la inflamación y el equilibrio redox.
- La evidencia emergente implica la vía Nrf2 en el desarrollo del cáncer, promoviendo la supervivencia de las células tumorales y la transformación maligna.
- La doble función de Nrf2 requiere una comprensión más profunda de las intervenciones terapéuticas específicas.
Objetivo del estudio:
- Aclarar los mecanismos moleculares y las funciones biológicas de Nrf2 en la patogénesis del cáncer.
- Revisar los avances recientes en la inhibición farmacológica de la actividad de Nrf2 para el tratamiento del cáncer.
- Discutir nuevos compuestos químicos y el progreso de los ensayos clínicos dirigidos a la vía Nrf2.
Principales métodos:
- Revisión de la literatura sobre los mecanismos moleculares que regulan el Nrf2.
- Análisis del papel de Nrf2 en la biología y la progresión del cáncer.
- Estudio de los estudios preclínicos y clínicos sobre los inhibidores de Nrf2 en el tratamiento del cáncer.
Principales resultados:
- Descripción detallada de las redes reguladoras de Nrf2 y sus funciones procancerígenas.
- Identificación de varias moléculas químicas diseñadas para bloquear la actividad de Nrf2.
- Resumen del estado actual de las terapias dirigidas a Nrf2 en los ensayos oncológicos.
Conclusiones:
- La inhibición farmacológica de Nrf2 presenta una vía terapéutica prometedora para los cánceres asociados con el estrés oxidativo y la inflamación.
- Dirigirse a Nrf2 podría interrumpir los mecanismos de supervivencia de las células cancerosas e impedir la progresión del tumor.
- La investigación adicional y la evaluación clínica son cruciales para optimizar las terapias contra el cáncer dirigidas a Nrf2.
Más Videos Relacionados
Videos de Conceptos Relacionados
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:46Electron Transport Chain: Complex I and II
15.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
15.0K
02:38Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K